BG101803A - Use of melatonin for treating patients suffering from drug addiction - Google Patents
Use of melatonin for treating patients suffering from drug addictionInfo
- Publication number
- BG101803A BG101803A BG101803A BG10180397A BG101803A BG 101803 A BG101803 A BG 101803A BG 101803 A BG101803 A BG 101803A BG 10180397 A BG10180397 A BG 10180397A BG 101803 A BG101803 A BG 101803A
- Authority
- BG
- Bulgaria
- Prior art keywords
- melatonin
- drug
- patient
- patients suffering
- treating patients
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003987 melatonin Drugs 0.000 title abstract 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 3
- 206010013663 drug dependence Diseases 0.000 title 1
- 208000011117 substance-related disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 5
- 229940079593 drug Drugs 0.000 abstract 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 2
- 229940049706 benzodiazepine Drugs 0.000 abstract 2
- 206010012335 Dependence Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Melatonin is used in the manufacture of a medicament fortreating a multidrug addict, or a patient who has symptoms ofhaving become dependent on, tolerant of, or addicted to abenzodiazepine drug, or for treating a patient who has beenclinically diagnosed as having a condition susceptible toalleviation by administration of a benzodiazepine drug, whilesimultaneously preventing the occurrence in the patient ofsymptoms of dependence on, tolerance of, or addiction to saidbenzodiazepine drug. The invention further relates to apharmaceutical formulation for the above-stated purposes, whichcomprises at least one diluent, carrier or adjuvant and as activeingredients a benzodiazepine drug and melatonin.9 claims
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/381,535 US6469044B1 (en) | 1995-02-01 | 1995-02-01 | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| EP95303853A EP0724878B1 (en) | 1995-02-01 | 1995-06-06 | Use of melatonin for treating patients suffering from drug dependencies |
| PCT/IB1996/000082 WO1996023496A1 (en) | 1995-02-01 | 1996-01-29 | Use of melatonin for treating patients suffering from drug addiction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG101803A true BG101803A (en) | 1998-04-30 |
| BG62876B1 BG62876B1 (en) | 2000-10-31 |
Family
ID=26140195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG101803A BG62876B1 (en) | 1995-02-01 | 1997-07-30 | The application of melatonin for the treatment of patients with medicament addiction |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JP4516159B2 (en) |
| CN (1) | CN1083263C (en) |
| AT (1) | AT408188B (en) |
| AU (1) | AU695366B2 (en) |
| BG (1) | BG62876B1 (en) |
| BR (1) | BR9607169A (en) |
| CZ (1) | CZ291349B6 (en) |
| DK (1) | DK176081B1 (en) |
| EE (1) | EE03384B1 (en) |
| FI (1) | FI119586B (en) |
| IS (1) | IS1980B (en) |
| LU (1) | LU90118B1 (en) |
| LV (1) | LV11940B (en) |
| MD (1) | MD1716C2 (en) |
| NO (1) | NO312814B1 (en) |
| NZ (1) | NZ298878A (en) |
| PL (1) | PL183148B1 (en) |
| SI (1) | SI9620022A (en) |
| SK (1) | SK284521B6 (en) |
| TR (1) | TR199700723T1 (en) |
| TW (1) | TW483757B (en) |
| WO (1) | WO1996023496A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU782266B2 (en) | 2000-01-05 | 2005-07-14 | Neurim Pharmaceuticals (1991) Ltd. | Method and formulation for treating resistance to antihypertensives and related conditions |
| IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Composition for treating insomnia |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| US8785492B2 (en) | 2012-01-26 | 2014-07-22 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| US11918557B2 (en) | 2012-01-26 | 2024-03-05 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| AU2013361459A1 (en) | 2012-12-18 | 2015-07-02 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| US10376487B2 (en) | 2013-11-12 | 2019-08-13 | Vanda Pharmaceuticals Inc. | Method of treatment |
| US11090285B2 (en) | 2013-11-12 | 2021-08-17 | Vanda Pharmaceuticals Inc | Treatment of circadian rhythm disorders |
| RS61024B1 (en) * | 2016-10-31 | 2020-12-31 | Neurim Pharma 1991 | Melatonin mini-tablets and method of manufacturing the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2134789T3 (en) * | 1991-05-09 | 1999-10-16 | Neurim Pharma 1991 | COMPOSITIONS CONTAINING MELATONIN. |
| IT1251544B (en) * | 1991-05-13 | 1995-05-17 | Gabriele Biella | PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE |
-
1996
- 1996-01-29 AU AU44574/96A patent/AU695366B2/en not_active Expired
- 1996-01-29 CN CN96191750A patent/CN1083263C/en not_active Expired - Lifetime
- 1996-01-29 WO PCT/IB1996/000082 patent/WO1996023496A1/en not_active Ceased
- 1996-01-29 SK SK1030-97A patent/SK284521B6/en unknown
- 1996-01-29 JP JP52338596A patent/JP4516159B2/en not_active Expired - Lifetime
- 1996-01-29 EE EE9700166A patent/EE03384B1/en not_active IP Right Cessation
- 1996-01-29 CZ CZ19972405A patent/CZ291349B6/en not_active IP Right Cessation
- 1996-01-29 BR BR9607169A patent/BR9607169A/en not_active Application Discontinuation
- 1996-01-29 TR TR97/00723T patent/TR199700723T1/en unknown
- 1996-01-29 NZ NZ298878A patent/NZ298878A/en not_active IP Right Cessation
- 1996-01-29 AT AT0901396A patent/AT408188B/en not_active IP Right Cessation
- 1996-01-29 PL PL96321630A patent/PL183148B1/en unknown
- 1996-01-29 SI SI9620022A patent/SI9620022A/en not_active IP Right Cessation
- 1996-01-29 MD MD97-0254A patent/MD1716C2/en not_active IP Right Cessation
- 1996-04-12 TW TW085104319A patent/TW483757B/en not_active IP Right Cessation
-
1997
- 1997-07-24 LV LVP-97-144A patent/LV11940B/en unknown
- 1997-07-25 IS IS4532A patent/IS1980B/en unknown
- 1997-07-30 BG BG101803A patent/BG62876B1/en unknown
- 1997-07-30 DK DK199700896A patent/DK176081B1/en not_active IP Right Cessation
- 1997-07-31 NO NO19973531A patent/NO312814B1/en not_active IP Right Cessation
- 1997-07-31 FI FI973185A patent/FI119586B/en not_active IP Right Cessation
- 1997-08-01 LU LU90118A patent/LU90118B1/en active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO306457B1 (en) | 2,4-disulfonylphenylbutylnitron, salts thereof, pharmaceutical composition, and the use of this compound in the manufacture of a medicament | |
| AU677279B2 (en) | Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes | |
| CA2114014A1 (en) | Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine | |
| MY106075A (en) | A method of treating anxiety-related disorders using sertraline. | |
| Yajnik et al. | Phenytoin as a coanalgesic in cancer pain | |
| BG101803A (en) | Use of melatonin for treating patients suffering from drug addiction | |
| RO116771B1 (en) | Method for preventing or treating the addiction on, tolerance or abuse of benzodiazepines | |
| NO308644B1 (en) | Use of 4-aminopyridine for the preparation of a pharmaceutical composition | |
| EE9700366A (en) | Use of angiotensin type II receptor antagonists in the manufacture of a medicament for the prophylaxis and / or treatment of dyspeptic symptoms and pharmaceutical preparations containing angiotensin type II receptor antagonists | |
| PH31051A (en) | Agents for treating substance abuse disorders. | |
| WO1996023496B1 (en) | Use of melatonin for treating patients suffering from drug addiction | |
| JPS6483020A (en) | Medicinal composition for preventing or treating aids | |
| Neill | Postoperative analgesia following brachial plexus block | |
| CA2211839A1 (en) | Use of melatonin for treating patients suffering from drug addiction | |
| GR3024854T3 (en) | Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances. | |
| Fink et al. | Opiate antagonists in the treatment of heroin dependence | |
| DK0457336T3 (en) | New use of 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olate | |
| EP0987022A4 (en) | DRUGS FOR THE PREVENTION OR TREATMENT OF HEMORRHAGIC RECTO-COLITIS AND / OR CROHN'S DISEASE | |
| UA10436A (en) | Method for treating gastric and duodenal ulcer | |
| UA6981A (en) | METHOD OF HEMOSORPTION |